Dimensional Fund Advisors LP Sells 407 Shares of Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC)

Dimensional Fund Advisors LP lessened its stake in shares of Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) by 0.6% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 63,656 shares of the company’s stock after selling 407 shares during the period. Dimensional Fund Advisors LP’s holdings in Tabula Rasa HealthCare were worth $2,727,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Principal Financial Group Inc. raised its holdings in Tabula Rasa HealthCare by 3.4% during the fourth quarter. Principal Financial Group Inc. now owns 154,463 shares of the company’s stock worth $6,617,000 after acquiring an additional 5,016 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Tabula Rasa HealthCare by 44.7% in the fourth quarter. JPMorgan Chase & Co. now owns 11,043 shares of the company’s stock valued at $473,000 after buying an additional 3,410 shares during the period. Truist Financial Corp raised its stake in Tabula Rasa HealthCare by 16.0% in the fourth quarter. Truist Financial Corp now owns 25,194 shares of the company’s stock valued at $1,079,000 after buying an additional 3,469 shares during the period. Jane Street Group LLC bought a new stake in Tabula Rasa HealthCare in the fourth quarter valued at approximately $794,000. Finally, Squarepoint Ops LLC raised its stake in Tabula Rasa HealthCare by 115.5% in the fourth quarter. Squarepoint Ops LLC now owns 16,454 shares of the company’s stock valued at $705,000 after buying an additional 8,820 shares during the period. Institutional investors and hedge funds own 93.34% of the company’s stock.

Shares of TRHC opened at $41.79 on Friday. Tabula Rasa HealthCare, Inc. has a 52 week low of $30.12 and a 52 week high of $69.31. The company has a market cap of $1.04 billion, a PE ratio of -10.83 and a beta of 0.94. The company has a quick ratio of 1.31, a current ratio of 1.38 and a debt-to-equity ratio of 4.02. The firm has a fifty day moving average price of $43.51.

Tabula Rasa HealthCare (NASDAQ:TRHC) last announced its earnings results on Thursday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.09). The business had revenue of $76.70 million during the quarter, compared to analyst estimates of $76.20 million. Tabula Rasa HealthCare had a negative return on equity of 23.88% and a negative net margin of 28.57%. Tabula Rasa HealthCare’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period last year, the company earned $0.01 EPS. On average, research analysts anticipate that Tabula Rasa HealthCare, Inc. will post -1.03 earnings per share for the current fiscal year.

In other Tabula Rasa HealthCare news, CEO Calvin H. Knowlton sold 10,000 shares of the stock in a transaction dated Thursday, May 20th. The stock was sold at an average price of $40.74, for a total transaction of $407,400.00. Following the completion of the sale, the chief executive officer now directly owns 841,360 shares in the company, valued at approximately $34,277,006.40. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, President Orsula V. Knowlton sold 8,000 shares of the stock in a transaction dated Monday, April 19th. The stock was sold at an average price of $43.01, for a total value of $344,080.00. Following the sale, the president now owns 853,360 shares of the company’s stock, valued at $36,703,013.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 41,695 shares of company stock valued at $1,729,834. 10.20% of the stock is owned by corporate insiders.

Several equities analysts have recently commented on the company. Truist downgraded Tabula Rasa HealthCare from a “buy” rating to a “hold” rating and upped their target price for the company from $41.00 to $42.00 in a research report on Monday, March 1st. SVB Leerink upped their target price on Tabula Rasa HealthCare from $43.00 to $49.00 and gave the company a “market perform” rating in a research report on Monday, May 10th. Piper Sandler increased their price target on Tabula Rasa HealthCare from $41.00 to $45.00 and gave the stock a “neutral” rating in a research report on Friday, May 7th. Cantor Fitzgerald reissued a “neutral” rating and set a $40.00 price target on shares of Tabula Rasa HealthCare in a research report on Tuesday, March 2nd. Finally, Zacks Investment Research raised Tabula Rasa HealthCare from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 4th. Seven investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $53.18.

Tabula Rasa HealthCare Profile

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. The company operates through two segments, CareVention HealthCare and MedWise HealthCare. It offers EireneRx, a cloud-based medication decision-support and e-prescribing platform to access patient medication-related information; and MedWise software that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing programs or systems.

Recommended Story: If I purchase shares through a brokerage account, am I the holder of record?

Want to see what other hedge funds are holding TRHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC).

Institutional Ownership by Quarter for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.